A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Recruiting

Phase 1

Phase 2

HB0036A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

Sponsor:

Shanghai Huaota Biopharmaceutical Co., Ltd.

Code:

NCT05417321

Conditions

Advanced Solid Tumor

NSCLC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

HB0036

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-19. This information was provided to ClinicalTrials.gov by Shanghai Huaota Biopharmaceutical Co., Ltd. on 2025-01-03.